Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States

Clinical Infectious Diseases

Volumn 51, Issue 3, 2010, Pages 286-294

  Johnson, James R ^a,c   Johnston, Brian ^a,c   Clabots, Connie ^a,c   Kuskowski, Michael A ^b,d   Castanheira, Mariana ^e  

^a Infectious Diseases Section   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Pennsylvania State University   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN PARC; QUINOLONE DERIVATIVE; TRIMETHOPRIM DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ESCHERICHIA COLI PROTEIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; GENOTYPE; HOSPITAL PATIENT; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PHYLOGENY; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; BACTERIUM IDENTIFICATION; BIOSYNTHESIS; CLASSIFICATION; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA SEQUENCE; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; CEPHALOSPORINS; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; SEQUENCE ANALYSIS, DNA; UNITED STATES; VIRULENCE FACTORS;

EID: 77954707306     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653932     Document Type: Article

References (30)

1. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlooked epidemic. Microbes Infect 2003; 5:449-456.
2. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001; 135:41-50. (Pubitemid 32619282)
3. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone- resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 2006; 50:2251-2254.
4. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-166.
5. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-475.
6. Nicolas-Chanoine M-H, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-281.
7. Clermont O, Lavollay M, Vimont S, et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61:1024-1028.
8. Clermont O, Dhanji H, Upton M, et al. Rapid detection of the O25b- ST131 clone of Escherichia coli encompassing theCTX-M-15-producing strains. J Antimicrob Chemother 2009; 64:274-277.
9. Coque TM, Novais Å, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum b-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.
10. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial- resistant urinary tract infections in Canada, 2002-2004. Antimicrob Agents Chemother 2009; 53:2733-2739.
11. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25: H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008; 46:2605-2612.
12. Lewis JS, 2nd, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007; 51:4015-4021.
13. CTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 2008; 14:211-216.
14. Vigil KJ, Johnson JR, Johnston B, et al. Escherichia coli pyomyositis: an emerging entity among patients with hematologic malignancies. Clin Infect Dis 2010; 50:374-380.
15. Ender PT, Gajanana D, Johnston B, Clabots C, Tamarkin FJ, Johnson JR. Transmission of extended-spectrum beta-lactamase-producing Escherichia coli (sequence type ST131) between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 2009; 47:3780-3782.
16. Clinical Laboratory Standards Institute. M100-S19. Performance standards for antimicrobial susceptibility testing. 19th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
17. Clinical Laboratory Standards Institute. M02-A10. Performance standards for antimicrobial disk susceptibility tests; approved standardtenth edition.Wayne, PA: Clinical Laboratory Standards Institute, 2009.
18. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66:4555-4558.
19. Johnson JR, Johnston B, Kuskowski MA, Nougayrede J-P, Oswald E. Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks genomic island. J Clin Microbiol 2008; 46:3906-3911.
20. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181:261-272.
21. Leflon-Guibout V, Jurand C, Bonacorsi S, et al. Emergence and spread of three clonally related virulent isolates of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosides and tetracycline in a French geriatric hospital. Antimicrob Agents Chemother 2004; 48: 3736-3742.
22. Blattner FR, Plunkett G, Bloch CA, et al. The complete genome sequence of Escherichia coli K-12. Science 1997; 277:1453-1474.
23. Ribot EM, Fair MA, Gautom R, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157: H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis 2006; 3:59-67.
24. Peakall R, Smouse PE. GENALEX 6: genetic analysis in Excel: population genetic software for teaching and research. Mol Ecol Notes 2006; 6:288-295.
25. Manges AR, Tabor H, Tellis P, Vincent C, Tellier P-P. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emerg Infect Dis 2008; 14:1575-1583.
26. Maslow JN, Whittam TS, Gilks CF, et al. Clonal relationships among bloodstream isolates of Escherichia coli. Infect Immun 1995; 63: 2409-2417.
27. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaffer AJ, Stamm WE. Guidelines for antimicrobial therapy of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29:745-758.
28. Johnson JR, Clermont O, Menard M, Kuskowski MA, Picard B, Denamur E. Experimental mouse lethality of Escherichia coli isolates, in relation to accessory traits, phylogenetic group, and ecological source. J Infect Dis 2006; 194:1141-1150.
29. Russo TA, Johnson JR. A proposal for an inclusive designation for extraintestinal pathogenic Escherichia coli: ExPEC. J Infect Dis 2000; 181:1753-1754.
30. Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infect Dis 2003; 188:759-768.